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Abstract
Introduction
National guidelines call for annual lung cancer screening for high-
risk smokers using low-dose computed tomography (LDCT). The
objective of our study was to characterize patient knowledge and
attitudes about  lung cancer  screening,  smoking cessation,  and
shared decision making by patient and health care provider.
Methods
We conducted semistructured qualitative interviews with patients
with histories of heavy smoking who received care at a Federally
Qualified Health Center (FQHC Clinic) and at a comprehensive
cancer center-affiliated chest clinic (Chest Clinic) in Albuquerque,
New Mexico. The interviews, conducted from February through
September 2014, focused on perceptions about health screening,
knowledge and attitudes about LDCT screening, and preferences
regarding decision aids. We used a systematic iterative analytic
process to identify preliminary and emergent themes and to create
a coding structure.
Results
We reached thematic  saturation after  22 interviews (10 at  the
FQHC Clinic,  12 at  the Chest  Clinic).  Most  patients  were un-
aware of LDCT screening for lung cancer but were receptive to
the test. Some smokers said they would consider quitting smoking
if their screening result were positive. Concerns regarding screen-
ing were cost, radiation exposure, and transportation issues. To
support decision making, most patients said they preferred one-on-
one discussions with a provider. They also valued decision sup-
port tools (print materials, videos), but raised concerns about read-
ability and Internet access.
Conclusion
Implementing lung cancer screening in sociodemographically di-
verse populations poses significant challenges. The value of to-
bacco cessation counseling cannot be overemphasized. Effective
interventions for shared decision making to undergo lung cancer
screening will  need the active engagement of  health care pro-
viders  and will  require the use of  accessible decision aids de-
signed for people with low health literacy.
Introduction
Despite advances in treatment and management, lung cancer re-
mains the most common cause of cancer-related disease and death
in the United States (1). Most lung cancer deaths are attributed to
smoking (2). Although recently declining smoking rates may re-
duce lung cancer incidence (1), former smokers remain at a high
risk  for  the  disease,  and  most  lung  cancers  occur  in  former
smokers (3).
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Until recently, no effective screening method existed for detecting
early-stage  lung  cancer  (4).  The  multicenter  National  Lung
Screening  Trial  (NLST)  enrolled  53,454  high-risk  smokers,
defined as people aged 55 to 74 years with a 30 pack year smoking
history, who were either current smokers or had quit within the
previous 15 years (5). Lung cancer deaths among NLST parti-
cipants  randomly assigned to low-dose computed tomography
(LDCT)  were  significantly  reduced  (16.0% [relative]  (6)  and
0.33% [absolute] (5) risk decrease) compared with those who had
chest x-ray. However, concerns remain regarding the high false
positive rates and complications following invasive diagnostic
procedures (ie, percutaneous biopsy, bronchoscopy, or surgical
procedure) (5).
Based on the NLST results, the United States Preventive Services
Task Force (USPSTF) issued a Grade B recommendation support-
ing LDCT screening for high-risk adults from 55 to 80 years of
age (7). The recommendation is important since the Affordable
Care Act mandates coverage without copayment for preventive
services that have a USPSTF recommendation of B or higher (8).
Guided by the USPSTF recommendation, the Centers for Medi-
care and Medicaid Services (CMS) now provide annual coverage
for lung cancer screening, with a requirement of a shared decision-
making visit (ie, consultation between patient and health care pro-
vider), for beneficiaries meeting NLST eligibility criteria (9). The
CMS directive also stipulates smoking cessation counseling and
the use of decision aid(s) to discuss potential screening outcomes
(9). The American Lung Association (10) and the American Can-
cer Society (11) also endorsed lung cancer screening for patients
meeting the NLST eligibility criteria. Both organizations recom-
mended both informed and shared decision making with clini-
cians and smoking cessation counseling (10,11).
Although there is a need to promote shared decision making for
lung cancer screening (10,11), gaps exist in our understanding
about how best to concisely and clearly present complex probabil-
ity-based screening information (eg, lung cancer risk, false posit-
ives, consequences of diagnostic follow-up), while effectively in-
tegrating smoking cessation messages. Moreover, it is important to
better understand the perspective of persons who are demograph-
ically different from those included in the NLST, the majority of
whom were non-Hispanic white (91%) and male (59%) (5). To de-
velop  appropriate  decision-support  strategies,  perspectives  of
people from diverse sociodemographic backgrounds need to be in-
corporated.  New Mexico,  as one of the 4 “majority–minority”
states, features unique multiethnic and multicultural diversity with
striking health and socioeconomic disparities. Lung cancer is a
leading cause of cancer death among minority populations in New
Mexico (12). We interviewed patients in clinics to characterize
their knowledge and attitudes about LDCT lung cancer screening
and smoking cessation and their  views on supporting decision
making for  lung cancer  screening.  We previously reported on
primary care providers’ perspectives about implementing LDCT
screening (13).
Methods
Study setting and sample
We conducted qualitative semistructured interviews with a di-
verse sample of patients who were receiving care at one of two
settings  in  Albuquerque,  New Mexico:  a  Federally  Qualified
Health Center (FQHC Clinic) or the University of New Mexico
Comprehensive  Cancer  Center  (UNMCCC)  Multidisciplinary
Chest Clinic (Chest Clinic). In New Mexico, the University of
New Mexico in Albuquerque is the only academic medical center
and is host to the only National Cancer Institute Comprehensive
Cancer Center in the state. This poses access issues for rural pa-
tients. At the time of this study, neither the FQHC Clinic nor the
Chest Clinic offered LDCT for lung cancer screening, nor were we
aware of any comprehensive screening program in the state. The
FQHC Clinic is part of the Research Involving Outpatient Set-
tings Network (RIOS Net), the Practice-Based Research Network
of New Mexico that predominantly serves Hispanic patients. By
using a purposeful sampling approach, we identified, recruited,
and interviewed adults aged 50 to 80 years with a history of heavy
smoking who met NLST enrollment criteria (5). Eligible parti-
cipants recruited from the FQHC Clinic self-reported not having
lung cancer or nodules and not having undergone a lung com-
puted tomography (CT) scan. Those recruited from the Chest Clin-
ic were documented to have had abnormal results from a lung CT
scan. Selecting a wide spectrum of at-risk patients enabled us to
include perspectives of patients ranging from those considering
screening to those who actually underwent the imaging and invas-
ive diagnostic testing that would be part of a screening program.
These perspectives were necessary to develop comprehensive de-
cision support tools to inform patients about screening and surveil-
lance testing and associated invasive diagnostic procedures. The
University of New Mexico Health Science Center’s Human Re-
search Protections Office approved all aspects of the research pro-
tocol.
Data collection
We developed an interview guide that focused on the domains of
knowledge and attitudes regarding LDCT lung cancer screening:
perceived risk from diagnostic testing (including radiation expos-
ure and complications from invasive diagnostic tests), views about
the benefits and harms of lung cancer screening, and views about
barriers and facilitators to smoking cessation or preventing re-
lapse, particularly in the context of lung cancer screening. We also
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elicited views about  the  value,  content,  format,  and timing of
providing patient decision-making aids and preferences for dis-
cussing screening. Before the interview, we administered a survey
that collected sociodemographic information. The survey and in-
terview guide are available from the corresponding author.
Three members of the research team (A.L.S., A.M.M., C.M.G.)
conducted the interviews from February through September 2014.
Each  digitally  audio-recorded  interview lasted  from 45  to  60
minutes and was transcribed for analytic review. We conducted in-
person interviews at the participant’s choice of location. Each par-
ticipant received a $50 merchandise card.
Data analysis
We used a systematic iterative process to identify preliminary and
emergent themes of importance (14). Several research team mem-
bers independently read sets of 2 or 3 transcripts to identify pre-
liminary  findings  (S.I.M.,  A.L.S.,  A.M.M.,  C.M.G.,  R.R.,
R.M.H.), which facilitated confirmation of emergent themes and
modifications to the interview guide. Through an iterative process
of reviewing additional transcripts, we created an initial coding
structure that was then revised until we reached consensus (15).
We then imported all the transcripts into NVivo 10 (QSR Interna-
tional), a qualitative data analysis software program, for coding.
After coding all transcripts, we queried the database by coding cat-
egories for a more refined level of interpretive analysis. We ana-
lyzed the quantitative survey data to produce a descriptive assess-
ment of the study sample.
Results
Sociodemographic characteristics of participants
and their views on cancer screening
We interviewed 22 clinic patients, 12 from Chest Clinic and 10
from FQHC Clinic. Table 1 presents their sociodemographic char-
acteristics. We categorized the qualitative interview findings into
major themes, which were described by FQHC and Chest Clinic
participants (Table 2). Participants in both clinics endorsed the
general importance of screening for health problems, even if they
personally did not undergo regular screening, because it “may re-
veal something unpleasant, but still it is good to know” to “catch
things  early.”  Some participants  previously  underwent  cancer
screening  tests  such  as  colonoscopy,  mammography,  or  Pap
smear; for one participant, this led to early cancer diagnosis and
treatment. Not surprisingly, participants identified barriers to en-
gaging in screening such as the cost of purchasing insurance, lack
of transportation, and low health literacy (eg, “they use big words
and I don’t know what they mean”). They also generally noted
that screening was not a normal behavior among their family and
social networks.
Knowledge and receptivity to LDCT screening for
lung cancer
None of  the  participants  interviewed at  the  FQHC Clinic  had
heard about using LDCT to screen for lung cancer. During the in-
terview, we provided a brief explanation of LDCT screening, and
most participants were interested. Participants who were either un-
certain or conditional about whether they would undergo lung can-
cer screening expressed uncertainty about the value of screening
(in terms of the benefits and necessity) and logistics of the screen-
ing procedure. Other participants were favorably inclined toward
screening but were still concerned about costs and the accuracy of
the test. Those strongly indicating that they would undergo screen-
ing  were  concerned  for  their  health  given  the  known  con-
sequences of long-term tobacco use.
Most Chest Clinic participants were unaware of LDCT screening.
However, receptivity to receiving the test was generally high, es-
pecially if the test was recommended by a health care provider.
Several participants reported being more inclined to undergo LD-
CT screening (and other  screening tests)  because of  a  general
sense of vulnerability that they attributed to their current situation
(ie, being under surveillance for lung cancer or having a diagnosis
of lung cancer) or their experience with other health problems.
Challenges to LDCT screening for lung cancer
In discussions with FQHC Clinic participants concerns about high
costs, radiation exposure, and psychological distress (stress, anxi-
ety) all emerged as considerations about whether to undergo LD-
CT screening. Most participants were not dissuaded by the poten-
tial for false positives and the need for continuous followup and
screening. We provided a brief explanation of LDCT screening
but did not review specific details (eg, false positives, followup
testing for positive scans). However, based on interviewer debrief-
ing notes following the discussions, it was unclear whether all par-
ticipants fully understood the meaning and implications of these
terms (eg, false positives, followup testing for positive scans).
Chest Clinic participants identified several factors that could pose
challenges to LDCT screening. They were particularly mindful
about costs but said they would make sacrifices to obtain neces-
sary care. As one participant noted, “I need to know if I have it or
not . . . I’ll deal with the money part of issues and aftercare when I
get to that.” Other challenges mentioned were the cost of treat-
ment, transportation issues, distance to the screening site, being
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able to trust health care providers, taking tests that were inconclus-
ive or invasive, and the need for annual screening. Participants
were generally not concerned about radiation exposure, false pos-
itives, or the need for continued follow-up and screening.
Smoking cessation in the context of LDCT for lung
cancer
We also explored views about how LDCT results — either posit-
ive or negative — might influence smoking behavior. FQHC Clin-
ic participants indicated that undergoing screening by itself might
not be a strong deterrent to smoking. However, several felt that a
positive test result might be sufficient motivation for a quit at-
tempt. Participants further noted that actually seeing a lung nod-
ule on an image would serve as a more powerful message that
something is wrong than just being told of a problem. Several in-
dicated that even a normal test result would not be sufficiently re-
assuring  and  that  they  would  still  consider  quitting  smoking.
However, participants expressing a fatalistic worldview might not
be swayed into considering quitting. Chest Clinic participants ex-
pressed similar views about LDCT screening and smoking cessa-
tion. Of these 12 participants, 9 were no longer smokers and 5 had
quit smoking because of a major scare (eg, receiving test results
about a suspicious lung nodule, having a friend or family member
with diagnosed lung cancer). Three Chest Clinic participants had
quit smoking since learning about a positive finding on an x-ray or
CT scan leading them to be seen at the Chest Clinic. However,
several participants believed that a negative screening result might
not  be  sufficient  to  persuade  someone  to  quit  smoking.  Con-
versely, a few participants lamented that such a finding could have
the opposite effect and serve as a green light to continue smoking.
Information needs and preferred communication
methods
After describing LDCT screening to participants, we then asked
them for input about the most important information to include in
a decision-making aid. FQHC Clinic participants suggested pic-
tures of a lung damaged by smoking, general information about
lung cancer, benefits and harms of LDCT screening, cost and dur-
ation of screening, and potential future treatment and treatment
side effects. Participants preferred learning about the screening
test in a face-to-face encounter with their health care provider.
Participants  also  suggested  pamphlets  or  written  materials;
however, they raised concerns about poor literacy and inability to
understand information. Others suggested using DVDs or CDs,
which someone could view in a doctor’s office and then seek clari-
fication from the doctor. They felt that a Web-based decision aid
might not be effective because of limited access to computers and
the Internet, a concern with particular relevance in a low-income
and rural state such as New Mexico.
Chest Clinic participants provided greater specificity regarding the
types of information that they would like to see in a decision aid,
including information about LDCT, risks and benefits of screen-
ing, false positives and negatives, and consequences of undergo-
ing the test. These participants preferred to receive screening in-
formation through one-on-one discussions with a health care pro-
vider.  Other  suggested  information sources  included booklets
(with pictures), videos, DVDs, and social media.
Discussion
This study presents findings from in-person qualitative interviews
of high-risk patients, with or without lung cancer, regarding LD-
CT screening for lung cancer, smoking cessation, and decision-
making support. The views summarized in this article are some of
the first from participants who were underrepresented in the NLST
and from patients not considered eligible by the NLST criteria (ie,
patients  with  a  lung nodule  or  lung cancer).  These interviews
provided insights into the screening process and perceptions re-
garding smoking cessation within the context of screening. The
findings  offer  insights  into  the  relative  value  of  focusing  on
smoking cessation counseling in the context of lung cancer screen-
ing, challenges to offering LDCT screening to sociodemographic-
ally diverse populations, and the content and structure of decision
aids.
A consistent message from guidelines (9–11) is that patients be
offered  smoking  cessation  counseling  along with  lung  cancer
screening.  Our  findings  provide  evidence  in  support  of  these
guidelines. Our findings suggest that smokers might attach person-
al benefits to lung cancer screening results, with negative findings
implying “got good news” and “I’m not a problem smoker” and
positive findings potentially motivating smokers to quit (16). Zeli-
adt et al (17), based on a qualitative study conducted at Veterans
Health Administration sites, also reported that negative screening
findings lowered participants’ motivation for cessation. Mean-
while, the Chest Clinic patients who had quit smoking all cited the
powerful effect of an abnormal finding, and many of the FQHC
Clinic smokers thought that abnormal findings could motivate ces-
sation. Indeed, the NLST reported that CT findings highly suspi-
cious  for  cancer  were  strongly  associated  with  subsequent
smoking cessation (18). Our findings point to the importance of
providing referrals for evidence-based smoking cessation interven-
tions (16) and also integrating smoking cessation counseling when
offering screening, discussing the results, and using these doctor-
patient interactions as a teachable moment for cessation counsel-
ing (19); primary care providers in a parallel arm of this study en-
dorsed this  referral  and counseling approach (13).  Ultimately,
achieving smoking cessation is likely to have a far greater public
health benefit than screening alone.
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Another  recommendation  from  the  lung  cancer  screening
guidelines (9–11) is the use of decision aids and shared decision
making between patient  and physician.  The lack of awareness
about lung cancer screening coupled with high receptivity for the
test among high-risk smokers underscores the need for decision
aids. Before our study, however, there was no evidence to guide
the content and structure of decision aids for lung cancer screen-
ing tailored for populations not recruited in the NLST. Our find-
ings provide evidence for inclusion of key areas in decision aids,
including a basic description of the LDCT screening test and how
it  is  conducted,  benefits  and harms of  screening,  sequence  of
events following an abnormal screen, visual depiction of damage
to the lungs from smoking, lungs with nodules or cancer, estim-
ated cost of screening and follow-up procedures, and a clear state-
ment about the benefits of smoking cessation regardless of screen-
ing results. Finally, our findings provide evidence for the need for
shared decision making and the need for health care providers to
actively engage eligible patients about smoking cessation and lung
cancer screening through one-on-one interactions. The shared de-
cision-making discussions should be supplemented with written
and audiovisual  (CD or DVD) aids to circumvent reading and
health literacy constraints, and these discussions should be tailored
to individual patient concerns and circumstances. A patient de-
cision aid (20) is being evaluated in a Patient-Centered Outcomes
Research Institute grant (21), and a Web-based (22) patient de-
cision aid needs further study to determine its efficacy and gener-
alizability.
Offering LDCT screening for lung cancer poses immense chal-
lenges. It is well-documented that participation in cancer screen-
ing is lower among racial/ethnic minorities than whites (23) and is
positively associated with cancer-specific and screening-specific
knowledge (24), proximity to screening centers (23), years of edu-
cation (23), high income (23), residence in urban areas (25), so-
cial support and normative behaviors that promote preventive be-
haviors (26), and private insurance (23). These positive predictors
for screening do not typify participants in our study who were pre-
dominantly Hispanic, unemployed, with low levels of education,
less normative behavior for preventive care, and on government
insurance (Medicaid). Furthermore, participants were unaware of
the existence of the LDCT screening test and identified additional
barriers to screening such as high costs, transportation barriers,
need for annual screening, and psychological distress. Therefore,
despite participants’ indicating their receptivity to LDCT screen-
ing, sociodemographic and psychosocial barriers may preclude
equitable delivery and uptake of lung cancer screening and may
further perpetuate lung cancer disparities.
The health equity issues related to people who do not resemble
those enrolled in the NLST may also extend to geographic areas.
Guidelines are clear that screening should not be offered except
through centers of excellence (7,11). Most NLST sites were uni-
versity or academic cancer centers. Other hospital centers in New
Mexico may not have sufficient resources and expertise to meet
the criteria necessary to offer lung cancer screening. This could
result in patchy national availability of lung cancer screening that
could further exacerbate disparities. The number of institutions na-
tionally having an active LDCT screening program are increasing
(27); however, concerns exist regarding screening use, infrastruc-
ture and resources to handle screening demands, and compliance
with recommended guidelines. Possible solutions could be to rely
more on telemedicine to ensure high-quality image interpretations
and to develop regional centers of excellence that could serve a
broader population. Applying more stringent criteria for screening
could also be beneficial by increasing the efficiency of screening.
A post-hoc analysis of the NLST data showed that the 3 highest
quintiles of risk accounted for 88% of the screening-prevented
lung-cancer deaths (28).
Our study has strengths and limitations. The findings from this
qualitative study are not representative or generalizable to other
types of clinical settings and do not represent the unique belief
systems and needs of sociodemographically diverse populations.
The results reported here are consistent and contextually relevant
perceptions of smoking cessation and lung cancer screening from
2 groups of high-risk patients and are necessary to guide future ef-
forts toward implementing LDCT screening, especially in popula-
tions and communities unlike those featured in the NLST study.
Although the National Cancer Institute excluded people with a his-
tory of lung cancer from the NLST, the American Association for
Thoracic Surgery (29) and the National Comprehensive Cancer
Network (30) recommend screening for lung cancer survivors.
Participants in our study represent a challenging population to
screen, especially in terms of access to care, health literacy, and
insurance coverage. These participants and associated findings fur-
ther underscore challenges in translating research into practice.
Implementing lung cancer screening programs among sociodemo-
graphically diverse populations will be challenging and could fur-
ther perpetuate lung cancer disparities. Value of smoking cessa-
tion counseling for current smokers within the context of lung can-
cer screening cannot be overemphasized, especially in light of the
evidence that positive screening findings might be viewed as a
motivation to quit. Screening programs will need literacy-appro-
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priate decision aids coupled with smoking cessation counseling
offered independently or conjointly in the context of lung cancer
screening. Policy makers should consider allocating greater re-
sources to smoking cessation interventions, especially in locations
where LDCT screening services cannot be offered in compliance
with recommended guidelines (9–11).
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Tables
Table 1. Participant (N = 22) Characteristics, Study of Patient Perspectives on Low-Dose Computed Tomography for Lung Cancer Screening, New Mexico, 2014
Characteristic Chest Clinic (n = 12), n FQHC Clinic (n = 10), n Clinics Combined (n = 22),
Age, mean (SD) 61.3 (10.31) 55.5 (3.98) 58.6 (8.43)
Sex
Male 6 7 13
Female 6 3 9
Race/ethnicity
Hispanic 5 9 14
White 6 1 7
African American 1 — 1
Marital status
Married or living with partner 5 1 6
Separated, divorced, widowed,  never
married
7 9 16
Employment
Employed (full- or part-time) 5 1 6
Unemployed 4 7 11
Retired 3 1 4
Refused to answer  — 1 1
Education
12 years or less 6 9 15
More than 12 years 6 1 7
Income
Less than $20,000 5 9 14
$20,000 or more 7 1 8
Insurance status
Medicaid 6 10 16
Medicare 4  — 4
Private 1  — 1
None 1  — 1
Currently use tobacco products
Yes 3 6 9
No 9 4 13
Abbreviations: —, not available; chest clinic, a comprehensive cancer center-affiliated chest clinic; FQHC, Federally Qualified Health Center; SD, standard deviation.
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Table 2. Examples of Participant Comments About Lung Cancer Screening, by Clinic Type, Study of Patients’ Perspectives on Low-Dose Computed Tomography for
Lung Cancer Screening, New Mexico, 2014
Theme Chest Clinic FQHC Clinic
General views on preventive
care (screening)
•“[It’s] especially like when you’re maybe 35, 40 years old,
that’s when people start opening their eyes. I think that as
you get older, people are more interested in, ‘yeah, let’s go
check something out.’”
 
“Well, I think that those are great. I get a colonoscopy
every five years and a mammogram every year.”
•
“I think more people would probably participate providing
they can afford it. When you mention medical to anybody,
the first thing they think of is, ‘here goes the money.’”
•
“Like my husband, he’s ‘oh, I’m superman. I don’t need to
go to the doctor’s’ and I’m telling him, ‘you don’t know
that, you may think everything’s fine.’”
•
“I’ve done mammograms, and I think that’s a good thing for
the women to do. I tell my daughter the same thing. I go, ‘you
need to take care of yourself.’”
•
“I had a . . . what do you call it? Borderline cancer of my cervix
at one time. I was younger, and I went for my Pap and they
told me I had an abnormal Pap.”
•
“I really, actually I don’t like doctors. I get scared about what
they’re gonna tell me, but now I’m at this age where I’m
having these symptoms and these things that are happening
to me. I’m more concerned about myself so I need to get
help.”
•
“No, they [family members] don’t go to the doctor as much as I
do.”
•
Knowledge and receptivity to
LCDT screening for lung
cancer
“I’m just now learning that they use chest x-ray and CT. Thirty
years ago, I’d say, ‘Ah, bullshit.’ I would usually tell somebody,
thanks, but I’m not interested. But I thought about it and you
know what? I’ll be generous enough to at least give you that.”
•
“[prior to a diagnosis of breast cancer, she would have said] ‘I
don’t need it.’ You know? I mean, that’s just it, you don’t
really think about it. You know? Until something happens.”
•
“I don’t think so. Oh, absolutely. Especially at my age. I think it
alleviates uncertainty. And when you’re referred and
scheduled for one of these, you really need to have answers. I
don’t work well with uncertainties.”
•
“There’s got to be some type of a screening for us smokers,
because when I went in last year, I didn’t have the spot on my
lung and if it was screened, it wouldn’t have gotten as big as
it did and I didn’t have symptoms and I still don’t. But I have
lung cancer. So CT screening would help, especially if you’re a
smoker.”
•
“Yes, I would if I can afford it. I’d rather do it because I want to
know what’s wrong with my health so we can fix it.”
•
“No [have not heard about it]. This is what I need. Bad. You
know it’s one thing to have a breathing problem, but it’s one
thing to know that without a referral you could get a scan and
check your lungs. Uh, accuracy. Benefit of the doubt. You
know straight up what’s wrong, what’s there and what’s not.”
•
“Uh . . . for lung cancer, no . . . I can’t believe I [have heard
about the test]. I’d have to think about it. I don’t know. I’d
have to weigh it out. I’d have to do the do’s and don’ts and I
don’t know. I have to think about it and who knows, I probably
would.”
•
“No [not heard]. No, I don’t think I want to do it. To be doing it
every year and every year, it’s gonna stay on your head. Every
year you can say you know, what’s gonna happen, what’s
gonna happen?”
•
Challenges to LDCT screening
for lung cancer
“Well I would think about the risks, depending on what it was,
but I have a lot of faith in my providers, I think I have really
good providers.”
•
“The false readings. The continued tests that aren’t
necessary.”
•
“The cost ‘cause nowadays, I mean, everything’s so
expensive. And if I have insurance, the insurance is gonna
cover it, it’ll be easier because, I mean, the CT scan is what,
about $1000? You have to have insurance, right? It’s money.
And if we don’t have the money to pay for the treatment or
what the case may be, you make it hard.”
•
“Like here in New Mexico that you are living in the middle of
nowhere. You have to travel 150 miles to get to the hospital. I
can see that those kind of people, especially since the
income rate within the state is as low as it is, especially for
older people which would be the type of people that need
this, and the . . . equipment, and technology that you need in
order to do the low dose scans isn’t something that you can
just roll out there in the middle of nowhere.”
•
“If I can afford it. I wouldn’t be able to get it if I had to pay for
it. I’d have some concern if I had to buy certain pills for it out
of my pocket; I wouldn’t be able to afford it.”
•
“False positives. Long screening, yeah, that’s a long time. The
radiation, too ‘cause I heard a lot of bad things about
radiation. The stress and the anxiety. Yeah, ‘cause I would be
thinking about that all the time it’s going on and I don’t even
like to go to doctor.”
•
“That I know I won’t get no cancer from the radiation. That’s
my main concern. You already explained to me that it’s light,
it’s not a heavy radiation, so that’s appealing to me in a
positive way as far as me doing it but, if it was like a high risk,
you know, I’d be like, no. No, they [false positives] don’t bother
me because I think that there’s a 50/50 chance.”
•
“What my health is that’d be my most important. If I’m sick I
want to know. The risk of how much that [radiation] would
jeopardize my health, too. I mean how much radiation are they
gonna give me? What is it gonna do to me, the side effects,
you know? That [annual screening] wouldn’t be a problem.”
•
Smoking cessation in the
Abbreviations: Chest Clinic: a comprehensive cancer center-affiliated chest clinic; CT, computed tomography; DVD, digital versatile disk; FQHC, Federally Qualified
Health Center; LDCT, low-dose computed tomography.
(continued on next page)
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(continued)
Table 2. Examples of Participant Comments About Lung Cancer Screening, by Clinic Type, Study of Patients’ Perspectives on Low-Dose Computed Tomography for
Lung Cancer Screening, New Mexico, 2014
Theme Chest Clinic FQHC Clinic
context of LDCT for lung
cancer
“No, and I think most people would be in that same boat. You
know, they got good news [ie, lungs are fine], so it didn’t help
them change nothing [ie, quit smoking]”
•
“No, I don’t think so. I think at that point I probably would
have still lit up the day before I went or the day of going to the
test. I would have probably thought about it after I had gotten
the CT scan and seeing what the results were. That’s just
where your mind’s set at and nothing scares you until you
hear that word, that big C word.”
•
“I would most likely keep smoking until they tell me that you
have to stop or this is what’s gonna happen. And if I go once a
year and if it shows I’m okay, most likely I’ll be smoking. If
they tell me it’s cancerous, now it’s like a rude awakening.
You have to stop.”
•
“Exactly and that’s how I would feel. That oh, that’s great.
Being honest with myself, if they told me today, ‘You don’t
have lung cancer,’ I wouldn’t go back and pick up the
cigarettes. I went through hell to get rid of them. But people
that are smoking were told, ‘No, your lungs are just fine.
There’s nothing wrong with them.’ I think most people would
go, ‘Whew. I thought they were going to tell me I had to quit.’”
•
“I don’t know. I think when somebody wants to quit they’ve
gotta just want to quit. I probably would [quit] if you showed
me how bad my lungs were and what I’ll look like in 3 more
years.”
•
“Oh hell yeah, that would tell me yay or nay, throw it away. [If
negative result] That means that I’m really not a problem
smoker. [If positive result] Just smoke a cigarette and think
about what it is, at least it’s got my attention. You know like
let’s say if it wasn’t quitting smoking and it’s only getting
worse, was the smoking keeping it at a minimum? I would
probably sit there and give it the 6-month lap. That means I
would still smoke, but a lot, lot less, so by the time the last 2
months of that 6 months come, I would be not smoking.”
•
“[If positive result] I hope it would really sink inside me and
say, ‘hey, you know what? You’ve got to quit’. [If negative
result] No, I think I would want to still quit. Because I say that,
‘hey, next week, boom, I could just get it.’”
•
“Yes. I’ll get a better understanding and a better reading about
what’s on the CT scan. I’ll get more feedback from a doctor,
from a professional. I think it would benefit me and help me
stop smoking even more if I knew that, that there is
complications that are going on.”
•
Information needs and
preferred communication
methods
“One-on-one, is the way that I want my information. I want my
information to come directly from my doctor or from the nurse
that I’m working with or the clinic I’m working with.”
•
“Probably the percentages of . . . the false readings. The
results of what happens when they get false readings.
Probably printed material. Face time with doctor.”
•
“All the information I could get . . . and in plain words, which I
could probably understand it, that would be the best.
Information about the test and the consequences and the
procedure itself time-wise. Most people do sit down a lot and
watch movies or DVDs. I think they would just like a 15
minute explanation of the procedure, how it’s done, why this
is being done, what kind of machine is gonna be used. The
doctor is the actual one that’s gonna give you the results.”
•
“I think there should be a lot more, instead of the smoking
cessation like the 1-800-QUIT NOW. They showed the guy with
the hole in the throat, the woman with the lung removed,
things like that, and then after that could be an informative
little message about if you [smoke] . . . this could be
prevented with a CT scan now. [A] family member should be
involved or family member to come with them, ‘cause the
family member will most likely talk them into it. For me I want
to know from the doctor. I think pamphlets in the doctor’s
office on the wall, like they have other pamphlets there,
because the longer you wait, the more you get bored and the
more you read.”
•
“Just show me pictures of lungs. People on more medication.
When I come into my appointments and I’m sitting down,
that’s how I read. Sometimes people won’t come to doctors,
because they just have a thing; for them I would say grocery
stores, where the ads are for the Quick Quarter or the cars.
Pamphlet there or something for smokers.”
•
“All the risk and the cost, but mostly the risk. “Maybe on a
DVD or something so you could watch, ‘cause sometimes a lot
of people don’t like to read. Like I don’t like to really read. The
doctor, too, but sometimes the doctors have certain amount of
time to talk to you. Sometimes some people don’t have [time]
for the Internet. They don’t have computers, I don’t have a
computer.”
•
“The correct information, the information that is stated on a
piece of paper and the information that is stated from a
professional. Information about the procedure, risks, benefits,
future treatment, side effects. A video, you know like a video
going through a facility like we’re here and you pull out a video
and say, ‘look, this is what it consists of.’ It could be a trained
health professional.”
•
“I know I’ve smoked for a long time. I don’t really know what
my lungs look like. If the people knew how bad their lungs
were, maybe they would think about it a little more. Pretty
much straight from my doctor, yeah I’d rather hear from him.
Reading it and stuff really just doesn’t hit you as like the
doctor telling you. You might have a question that you want to
ask, and with a video you won’t be able to ask any questions.”
•
Abbreviations: Chest Clinic: a comprehensive cancer center-affiliated chest clinic; CT, computed tomography; DVD, digital versatile disk; FQHC, Federally Qualified
Health Center; LDCT, low-dose computed tomography.
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